Brief: Temasek's Long Position In Ordinary Shares Of Clover Biopharmaceuticals Falls To 4.99% - Filing
18/11/2022 09:07
Nov 18 (Reuters) - Hong Kong stock exchange filing:
* TEMASEK HOLDINGS PRIVATE LIMITED'S LONG POSITION IN
ORDINARY
SHARES OF CLOVER BIOPHARMACEUTICALS 2197.HK REDUCED TO 4.99%
ON NOV 16 FROM 7.21% - HKEX FILING
Source text
Source text 2
Further company coverage: 2197.HK
(Reporting by Hong Kong newsroom)
((twinnie.siu@tr.com; 852-3462 7715;))
Recent news on Clover Biopharmaceuticals
See all newsChina's Clover Biopharma H1 revenue drops sharply, flags going-concern doubt
Brief: Clover Biopharmaceuticals Posts FY Loss Of RMB205.1 MLN
Brief: Clover Announces Positive Phase I Clinical Data For Rsv-Hmpv-Piv3 Combination Vaccines And For Rsv Re-Vaccination In Older Adults
Brief: Clover Biopharmaceuticals Posts H1 Revenue Of RMB3.3 Million
Brief: Clover Biopharmaceuticals Says It Terminates Cooperation With Adimmune